Search

Your search keyword '"Zer, Alona"' showing total 369 results
Start Over Author "Zer, Alona"
369 results on '"Zer, Alona"'

101. Rare targetable drivers (RTD) in NSCLC: PD-L1 expression, tumor mutation burden (TMB), microsatellite instability (MSI) and outcomes with immune check-point inhibitors (ICPi).

Author

Dudnik, Elizabeth, primary, Bshara, Elias, additional, Grubstein, Ahuva, additional, Fridel, Ludmila, additional, Shochat, Tzippy, additional, Roisman, Laila C, additional, Ilouze, Maya, additional, Rozenblum, Anna B, additional, Geva, Smadar, additional, Zer, Alona, additional, Rotem, Ofer, additional, Allen, Aaron, additional, and Peled, Nir, additional

Published
2018
Full Text
View/download PDF

102. Lung cancer in never smokers from the Princess Margaret Cancer Centre

Author

Korpanty, Grzegorz J., primary, Kamel-Reid, Suzanne, additional, Pintilie, Melania, additional, Hwang, David M., additional, Zer, Alona, additional, Liu, Geoffrey, additional, Leighl, Natasha B., additional, Feld, Ronald, additional, Siu, Lillian L., additional, Bedard, Philippe L., additional, Tsao, Ming-Sound, additional, and Shepherd, Frances A., additional

Published
2018
Full Text
View/download PDF

105. Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer

Author

Zer, Alona, primary, Pond, Gregory R., additional, Razak, Albiruni R. Abdul, additional, Tirona, Kattleya, additional, Gan, Hui K., additional, Chen, Eric X., additional, O’Sullivan, Brian, additional, Waldron, John, additional, Goldstein, David P., additional, Weinreb, Ilan, additional, Hope, Andrew J., additional, Kim, John J., additional, Chan, Kelvin K. W., additional, Chan, Andrew K., additional, Siu, Lillian L., additional, and Bernstein, Lori J., additional

Published
2017
Full Text
View/download PDF

109. OA21.02 ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism

Author

Zer, Alona, primary, Moskovitz, Mor, additional, Hwang, David, additional, Hershko-Klement, Anat, additional, Fridel, Ludmila, additional, Korpanty, Grzegorz, additional, Dudnik, Elizabeth, additional, Peled, Nir, additional, Shochat, Tzippy, additional, Leighl, Natasha, additional, Liu, Geoffrey, additional, Feld, Ronald, additional, Burkes, Ronald, additional, Wollner, Mira, additional, Tsao, Ming, additional, and Shepherd, Frances, additional

Published
2017
Full Text
View/download PDF

110. P3.02c-076 Correlation of Neutrophil to Lymphocyte Ratio (NLR) with Clinical Benefit from Checkpoint Inhibitors in Advanced Lung Cancer

Author

Zer, Alona, primary, Sung, Mike, additional, Walia, Kanwalpreet, additional, Khoja, Leila, additional, Maganti, Manjula, additional, Labbe, Catherine, additional, Shepherd, Frances, additional, Bradbury, Penelope, additional, Feld, Ronald, additional, Liu, Geoffrey, additional, Iazzi, Melissa, additional, Zawisza, Dianne, additional, Nouriany, Nazanin, additional, and Leighl, Natasha, additional

Published
2017
Full Text
View/download PDF

114. MA13.05 Nivolumab in Non-Small Cell Lung Cancer (NSCLC): The Real-Life Data

Author

Dudnik, Elizabeth, primary, Moskovitz, Mor, additional, Daher, Sameh, additional, Shamai, Sivan, additional, Hanovich, Ekaterina, additional, Shechtman, Yelena, additional, Abu-Amna, Mahmoud, additional, Zer, Alona, additional, Wollner, Mira, additional, Bar, Jair, additional, Merimsky, Ofer, additional, Cyjon, Arnold, additional, Shochat, Tzippy, additional, and Peled, Nir, additional

Published
2017
Full Text
View/download PDF

115. P3.07-004 Nivolumab for Non-Small Cell Lung Cancer (NSCLC): An Economic Model for Risk Sharing Based on Real-Life Data

Author

Dudnik, Elizabeth, primary, Goldstein, Daniel, additional, Roisman, Laila, additional, Hammerman, Ariel, additional, Greenberg-Dotan, Sari, additional, Bar, Jair, additional, Moskovitz, Mor, additional, Daher, Sameh, additional, Shamai, Sivan, additional, Hanovich, Ekaterina, additional, Shechtman, Yelena, additional, Abu-Amna, Mahmoud, additional, Zer, Alona, additional, Wollner, Mira, additional, Merimsky, Ofer, additional, Cyjon, Arnold, additional, and Peled, Nir, additional

Published
2017
Full Text
View/download PDF

117. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.

Author

Bedas, Aseel, Peled, Nir, Rabinovich, Natalie Maimon, Mishaeli, Moshe, Shochat, Tzippy, Zer, Alona, Rotem, Ofer, Allen, Aaron M., Bar, Jair, and Dudnik, Elizabeth

Subjects
CRIZOTINIB, NON-small-cell lung carcinoma, OLDER patients, PROTEIN-tyrosine kinases, ANAPLASTIC lymphoma kinase, KINASE inhibitors
Abstract

Background: Little is known regarding the anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) efficacy and safety in the elderly. Objectives and Methods: Consecutive patients (n = 53) with ALK-positive advanced non-small cell lung cancer treated with an ALK TKI were identified through internal databases of three cancer centers and divided into groups A (< 65 years old; n = 34) and B (=65 years old; n = 19). Progression-free survival (PFS), ALK TKI safety and overall survival (OS) were assessed. Uni- and multivariate PFS and OS analyses were performed. Results: Crizotinib, ceritinib, and alectinib were administered in 94 and 100%, 35 and 31%, 38 and 52% of patients in groups A and B, respectively. The median PFS (months) was 5.4 (95% CI, 3.4-12.4) and 5.6 (95% CI, 2.5-14.7) with crizotinib (log-rank 0.0009, p = 0.9), 4.7 (95% CI, 1.0-11.5) and 23.0 (95% CI, 0.8-27.7) with ceritinib (log-rank 0.44, p = 0.5), and 21.2 (95% CI, 1.2 to not reached, NR) and 5.6 (95% CI, 0.5 to NR) with alectinib (log-rank 0.53, p = 0.5) in groups A and B, respectively. The median OS (months) comprised 29.8 (95% CI, 21.0 to NR) and 25.1 (95% CI, 10.8-53.6) in groups A and B, respectively (logrank 0.57, p = 0.4). Age affected neither PFS nor OS. 19 and 37%, 50 and 40%, and 0 and 0% of patients in groups A and B, treated with crizotinib, ceritinib, and alectinib, respectively, developed high-grade adverse events. The treatment discontinuation rate was 9 and 21%, 16 and 60%, 0 and 0% with crizotinib, ceritinib, and alectinib in groups A and B, respectively. Conclusions: In the elderly, crizotinib, ceritinib, and alectinib treatments are associated with similar efficacy but different safety profiles; alectinib is associated with a lower rate of high-grade adverse events and a lower treatment discontinuation rate. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

118. MRI diagnosis and follow-up of chest wall and breast desmoid tumours in patients with a history of oncologic breast surgery and silicone implants: A pictorial report.

Author

Gadiel, Itay, Grubstein, Ahuva, Rapson, Yael, Atar, Eli, Zer, Alona, Morgenstern, Sara, and Gutman, Haim

Subjects
BREAST imaging, DESMOID tumors, MAGNETIC resonance imaging, SILICONES in surgery, ARTIFICIAL implants, BREAST tumors, BREAST implants, CHEST tumors, DIAGNOSTIC imaging, LONGITUDINAL method, MAMMAPLASTY, COMPUTERS in medicine, SILICONES, TREATMENT effectiveness, RETROSPECTIVE studies, CHEST (Anatomy), CONNECTIVE tissue tumors, TUMOR treatment
Abstract

Introduction: Breast and chest wall desmoid tumours can cause debilitating symptoms and deformity. The mutilating effects of surgical treatment have prompted a shift to medical treatments and even to a wait-and-see approach. This study sought to highlight specific characteristics of breast and chest wall desmoid tumours on long-term follow-up by sequential MRI scans.Methods: Thirty-two breast MRI scans from six patients with chest wall or breast desmoid tumours followed up for up to 6 years were retrospectively reviewed.Results: All patients underwent breast surgery prior to the development of the desmoid tumour. Five of the patients had reconstruction or augmentation using silicone implants. Two desmoids were treated primarily with surgery, three with medical means and one is under wait-and-see approach. On MRI, tumours appeared either oval and lobulated (chest wall) or spiculated with architectural distortion (breast). Chest wall desmoids demonstrated both an enhancing high-T2-signal component and a non-enhancing low-T2- signal component. The histologically defined phases during the course of desmoid tumours (progression, regression, residual disease) could be demonstrated by corresponding MRI changes in each of the components.Conclusions: Magnetic resonance imaging delineates the complex infiltrative features of chest wall and breast desmoid tumours. In tumours with a bright cellular enhancing and dark collagenous non-enhancing component, treatment response may be predicted by changes on serial T2-weighted sequences, beyond the tumour-dimension-based RECIST assessment alone. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

119. Primary cardiac sarcomas: A multi‐national retrospective review.

Author

Chen, Tom Wei‐Wu, Loong, Herbert H., Srikanthan, Amirrtha, Zer, Alona, Barua, Reeta, Butany, Jagdish, Cusimano, Robert J., Liang, Yun‐Chieh, Chang, Chin‐Hao, Iakobishvili, Zaza, Razak, Albiruni R. Abdul, and Lewin, Jeremy

Subjects
RARE diseases, ANGIOSARCOMA, PROPORTIONAL hazards models
Abstract

Background: Primary cardiac sarcoma (PCS) is a rare but often fatal disease. The current study aimed to analyze the impact of baseline demographics, local and systemic therapies in a contemporary cohort. Methods: Clinical records of PCS across six institutions in three continents were reviewed. Kaplan‐Meier method was used to estimate survival. Cox proportional hazard model was used to determine variables impacting progression‐free survival (PFS) or overall survival (OS). Results: Sixty‐one patients with PCS (1996‐2016) were identified. The median age at diagnosis was 46 (range 18‐79); 36% (n = 22) presented with metastatic disease. The most common histology was angiosarcoma (n = 24, 39%). A total of 46 patients received surgery (75%) but only 5 (8%) patients achieved R0 resection. Multi‐modality treatment to the primary tumor was given to 28 patients (46%; localized disease 23/39 (59%); metastatic disease 5/22 (23%)). The median OS for the entire cohort was 17.5 months (95% CI 9.5‐20.6), with seven (11%) patients surviving longer than 36 months. On multi‐variate analysis, age <65 (P = 0.01) was the only significant favorable prognostic factor. For first‐line palliative chemotherapy, the median PFS was 4.4 months (95% CI 2.9‐7.7 months). The best response for first‐line chemotherapy was 32% (CR = 1, PR = 9). No significant improvement in OS was identified in patients presenting throughout the 20‐year period of this review. Conclusion: Younger age at diagnosis was associated with improved outcome although the prognosis of PCS remains poor. Given the lack of improvement in survival, further dedicated research is required. Primary cardiac sarcoma (PCS) is a rare disease with poor prognosis. The survival had not improved in the past 20 years. Identification of prognostic factors and better treatment modalities to PCD is crucial to improve the outcome of PCS patients. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

122. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

Author

Gounder, Mrinal M., primary, Zer, Alona, additional, Tap, William D., additional, Salah, Samer, additional, Dickson, Mark A., additional, Gupta, Abha A., additional, Keohan, Mary Louise, additional, Loong, Herbert H., additional, D’Angelo, Sandra P., additional, Baker, Stephanie, additional, Condy, Mercedes, additional, Nyquist-Schultz, Kjirsten, additional, Tanner, Lanier, additional, Erinjeri, Joseph P., additional, Jasmine, Francis H., additional, Friedlander, Sharon, additional, Carlson, Robert, additional, Unger, Thaddeus J., additional, Saint-Martin, Jean-Richard, additional, Rashal, Tami, additional, Ellis, Joel, additional, Kauffman, Michael, additional, Shacham, Sharon, additional, Schwartz, Gary K., additional, and Abdul Razak, Albiruni Ryan, additional

Published
2016
Full Text
View/download PDF

126. High-Dose Radiotherapy as Neoadjuvant Treatment in Non-Small-Cell Lung Cancer.

Author

Flex, Dov, Allen, Aaron M., Zer, Alona, Peled, Nir, Dudnik, Elizabeta, Fenig, Eyal, Shochat, Tzippy, Kramer, Mordechai R., and Saute, Milton

Subjects
LUNG cancer treatment, LUNG cancer prognosis, ADENOCARCINOMA, CANCER relapse, CISPLATIN, COMBINED modality therapy, CONFIDENCE intervals, ETOPOSIDE, LUNG cancer, PNEUMONECTOMY, RADIATION doses, SQUAMOUS cell carcinoma, SURVIVAL, TUMOR classification, INSTITUTIONAL review boards, TREATMENT effectiveness, DISEASE progression, CHEMORADIOTHERAPY, THERAPEUTICS
Abstract

Background: Trimodality therapy (chemoradiation followed by surgery) provides a benefit in progression-free survival but not overall survival. We sought to determine if a high dose of radiation could be delivered safely and provide a clinical benefit. Methods: Consecutive patients with stage IIIA or IIIB non-small-cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy followed by surgery were reviewed with IRB approval. Results: A total of 48 patients were treated from November 2007 to May 2014. Of these, 64% had stage IIIA disease while 36% had stage IIIB; 46% had adenocarcinoma, 34% squamous, and 23% NSCLC not otherwise specified. The median dose of chemoradiotherapy was 72 Gy (60–72). Overall, 86% of patients received cisplatin (50 mg/m2) and etoposide (50 mg/m2) concurrently with radiotherapy; 72% of patients underwent lobectomy following chemoradiotherapy and 28% underwent pneumonectomy. The 30- and 90-day mortality rates were 0%. The nodal downstaging rate was 82% and there was a 64% rate of pathologic complete response. The overall survival was 29.9 months (95% CI, 19–86 months). The median time to locoregional progression was 35.1 months and the median time to distant progression was 39.3 months. Locoregional failure was 8% and distant failure was 44%. Conclusion: High-dose preoperative chemoradiotherapy was safe and effective. This combination should be further considered. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

128. A decision-making tool for first-line treatment in advanced non–small-cell lung cancer based on plasma proteome biomarkers.

Author

Sela, Itamar, Christopoulos, Petros, Puzanov, Igor, Bar, Jair, Zer, Alona, Moskovitz, Mor, Reinmuth, Niels, Lotem, Michal, Katzenelson, Rivka, Agbarya, Abed, Farrugia, David, Price, Gillian, Cheley, Helen, Abu-Amana, Mahmud, McGregor, Kimberly, Lou, Yanyan, Leibowitz, Raya, Dicker, Adam P., Carbone, David Paul, and Gandara, David R.

Published
2023
Full Text
View/download PDF

129. A phase 1b study with selinexor, a first in class selective inhibitor of nuclear export (SINE) in patients with advanced sarcomas: An efficacy analysis.

Author

Gounder, Mrinal M., primary, Zer, Alona, additional, Tap, William D., additional, Gupta, Abha A., additional, Keohan, Mary Louise, additional, Dickson, Mark Andrew, additional, D'Angelo, Sandra P., additional, Chi, Ping, additional, Tanner, Lanier R., additional, Konen, Theresa, additional, Rashal, Tami, additional, McCauley, Dilara, additional, Saint-Martin, Jean-Richard, additional, Carlson, Robert, additional, Marshall, Tracey, additional, Shacham, Sharon, additional, Mirza, Mansoor Raza, additional, Kauffman, Michael, additional, Schwartz, Gary, additional, and Razak, Albiruni R. A., additional

Published
2015
Full Text
View/download PDF

130. Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre.

Author

Korpanty, Grzegorz, primary, Kamel-Reid, Suzanne, additional, Tsao, Ming Sound, additional, Hwang, David M, additional, Zer, Alona, additional, Liu, Geoffrey, additional, Leighl, Natasha B., additional, Feld, Ronald, additional, Gill, Bethany, additional, Pintilie, Melania, additional, and Shepherd, Frances A., additional

Published
2015
Full Text
View/download PDF

132. A phase I study of BI 853520, an inhibitor of focal adhesion kinase (FAK), in patients with advanced or metastatic solid tumors.

Author

Zer, Alona, primary, Verheijen, Remy, additional, De Vos, Filip Yves Francine Leon, additional, Hotte, Sebastien, additional, Eskens, Ferry, additional, Pronk, Linda, additional, Siu, Lillian L., additional, Schnell, David, additional, Steeghs, Neeltje, additional, Langenberg, Marlies HG, additional, Hirte, Hal, additional, and De Jonge, Maja J., additional

Published
2015
Full Text
View/download PDF

135. Adjuvant Docetaxel and Cyclophosphamide (DC) with Prophylactic Granulocyte Colony-Stimulating Factor (G-CSF) on Days 8 &12 in Breast Cancer Patients: A Retrospective Analysis

Author

Yerushalmi, Rinat, primary, Goldvaser, Hadar, additional, Sulkes, Aaron, additional, Ben-Aharon, Irit, additional, Hendler, Daniel, additional, Neiman, Victoria, additional, Ciuraru, Noa Beatrice, additional, Bonilla, Luisa, additional, Amit, Limor, additional, Zer, Alona, additional, Granot, Tal, additional, Rizel, Shulamith, additional, and Stemmer, Salomon M., additional

Published
2014
Full Text
View/download PDF

137. Landscape of genomic alterations (GA) detected by next-generation sequencing (NGS) in non-small cell lung cancer (NSCLC) adenocarcinoma in Israel.

Author

Peled, Nir, primary, Nechushtan, Hovav, additional, Wollner, Mira, additional, Onn, Amir, additional, Flex, Dov, additional, Bar, Jair, additional, Gottfried, Maya, additional, Agbarya, Abed, additional, Zer, Alona, additional, Mishaeli, Moshe, additional, Segal, Amiel, additional, Dudnik, Julia, additional, Katzenelson, Rivka, additional, Dvir, Addie, additional, Soussan-Gutman, Lior, additional, Stephens, Phil, additional, Wang, Kai, additional, Miller, Vincent A., additional, and Ross, Jeffrey S., additional

Published
2014
Full Text
View/download PDF

139. A targeted intervention to improve awareness to molecular testing in NSCLC.

Author

Zer, Alona, primary, Cutz, Jean-Claude, additional, Sekhon, Harmanjatinder S., additional, Hwang, David M, additional, Sit, Christina, additional, Binnie, Matthew, additional, Brade, Anthony M., additional, Chung, TaeBong, additional, Kamel-Reid, Suzanne, additional, Narinder, Paul, additional, Tsao, Ming-Sound, additional, Waddell, Thomas K., additional, Santos, Gilda da Cunha, additional, Patel, Milan, additional, Carter, Ronald F, additional, and Leighl, Natasha B., additional

Published
2014
Full Text
View/download PDF

142. BRAFMutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Author

Dudnik, Elizabeth, Peled, Nir, Nechushtan, Hovav, Wollner, Mira, Onn, Amir, Agbarya, Abed, Moskovitz, Mor, Keren, Shoshana, Popovits-Hadari, Noa, Urban, Damien, Mishaeli, Moshe, Zer, Alona, Allen, Aaron M., Rabinovich, Natalie Maimon, Rotem, Ofer, Kuznetsov, Teodor, Shochat, Tzippy, Roisman, Laila C., and Bar, Jair

Abstract

The efficacy of immune checkpoint inhibitors (ICPi) in BRAFmutant NSCLC is unknown.

Published
2018
Full Text
View/download PDF

143. Adjuvant docetaxel and cyclophosphamide (DC) with prophylactic growth colony stimulating factor (GCSF) on days 8 and 12 in breast cancer patients: A retrospective analysis.

Author

Yerushalmi, Rinat, primary, Stemmer, Salomon M., additional, Hendler, Daniel, additional, Neiman, Victoria, additional, Ciuraru, Noa Beatrice, additional, Bonilla, Luisa, additional, Ben-Aharon, Irit, additional, Amit, Limor, additional, Granot, Tal, additional, Zer, Alona, additional, Sulkes, Aaron, additional, and Rizel, Shulamith, additional

Published
2012
Full Text
View/download PDF

146. Cardiac Mass in a Rapidly Deteriorating Patient

Author

Zer, Alona, primary, Green, Pnina, additional, Moreh-Rahav, Osnat, additional, Morgenstern, Sara, additional, Medalion, Benjamin, additional, Zilbermints, Veacheslav, additional, Allen, Aaron M., additional, and Stemmer, Salomon M., additional

Published
2010
Full Text
View/download PDF

147. Pooled Analysis of the Prognostic and Predictive Value of KRASMutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Author

Zer, Alona, Ding, Keyue, Lee, Siow Ming, Goss, Glenwood D., Seymour, Lesley, Ellis, Peter M., Hackshaw, Allan, Bradbury, Penelope A., Han, Lei, O’Callaghan, Christopher J., Tsao, Ming-Sound, and Shepherd, Frances A.

Abstract

This pooled analysis of four trials of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) versus placebo was conducted to clarify the prognostic and predictive roles of Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations (MUTs) and to explore the importance of MUT subtype.

Published
2016
Full Text
View/download PDF

148. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.

Author

Dudnik, Elizabeth, Bar, Jair, Peled, Nir, Bshara, Elias, Kuznetsov, Teodor, Cohen, Aharon Yonathan, Shochat, Tzippy, Nechushtan, Hovav, Onn, Amir, Agbarya, Abed, Moskovitz, Mor, Keren, Shoshana, Popovits-Hadar, Noa, Urban, Damien, Mishaeli, Moshe, Rabinovich, Natalie Maimon, Brenner, Ronen, Zer, Alona, Rotem, Ofer, and Roisman, Laila C.

Published
2019
Full Text
View/download PDF

149. A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS).

Author

Veitch, Zachary, Zer, Alona, Loong, Herbert, Salah, Samer, Masood, Maryam, Gupta, Abha, Bradbury, Penelope A., Hogg, David, Wong, Andrew, Kandel, Rita, Charames, George S., and Abdul Razak, Albiruni R.

Abstract

ENMD-2076, an aurora-A kinase inhibitor with anti-angiogenic properties, has shown activity in solid and hematologic malignancies. We investigated oral ENMD-2076 in an open-label, single-arm phase II study using 275 mg daily on a 28-day cycle in patients with advanced soft-tissue sarcomas (STS) receiving ≤1 line of prior therapy. Primary endpoint was 6-month progression-free survival (PFS) with ≤15% indicating no interest, and ≥40% indicating further interest in ENMD-2076. Secondary/exploratory endpoints included clinical benefit (CBR ≥6-months) and objective response (ORR) rates, PFS, OS, safety, and whole-exome sequencing (WES) for potentially associated biomarkers. Overall, 23/25 (92%) patients receiving ENMD-2076 were efficacy evaluable with median follow-up of 14 months (range 2.2–39.5). Common subtypes were leiomyosarcoma (n = 10), undifferentiated pleomorphic sarcoma (n = 3), angiosarcoma (n = 3), and alveolar soft-part sarcoma (n = 3). The 6-month PFS was 20.8% (95% CI:3.2–38.4) with a CBR of 17% (95% CI:1.55–33.23) and ORR of 9% (95% CI:3.08–20.46). Median PFS was 2.5 months (95% CI:2.20–4.47) and OS was 14.1 months (95% CI:6.07–20.07). The most common high-grade treatment-related adverse event was hypertension (60%). WES identified PTPRB mutations in 3/4 patients (p = 0.018) benefiting from ENMD-2076. Although this study failed to meet its primary endpoint, occasional responses and prolonged stable disease was noted. ENMD-2076 evaluation in PTPRB mutated tumors and/or angiosarcoma is warranted. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

150. Hospitalisations and emergency department visits in cancer patients receiving systemic therapy: Systematic review and meta‐analysis.

Author

Prince, Rebecca M., Powis, Melanie, Zer, Alona, Atenafu, Eshetu G., and Krzyzanowska, Monika K.

Subjects
AGE distribution, CANCER chemotherapy, CANCER patients, CRITICAL care medicine, HOSPITAL care, LENGTH of stay in hospitals, HOSPITAL emergency services, MEDICAL information storage & retrieval systems, MEDICAL appointments, MEDLINE, META-analysis, PALLIATIVE treatment, TUMORS, SYSTEMATIC reviews, COMORBIDITY, TREATMENT duration
Abstract

Emergency department visits and hospitalisations (ED+H) during systemic therapy are undesirable for both patients and the health system. We undertook a systematic literature review and meta‐analysis to evaluate the frequency of unplanned all‐cause and treatment‐related ED+H among adults receiving adjuvant or palliative‐intent systemic therapy for all cancers. Randomised controlled trials (RCT) and observational studies (OS) reporting ED+H were identified from Medline and EMBASE from inception to June 2016. Quality was assessed using modified STROBE, CONSORT or PRISMA guidelines, depending on study type. A total of 112 OS (308,662 patients) and 26 RCTs (16,081 patients) met inclusion criteria. Most articles focused on palliative treatment (59%) delivered as first‐line, in breast, lung and colorectal cancers. Only 20 articles reported ED frequency. Treatment‐related and all‐cause hospitalisations were more common in routine practice than in RCTs (29% vs. 16% and 42% vs. 28% respectively); frequency varied by treatment intent and tumour site. Methodological issues were common, particularly poor definition of the at‐risk period. Hospitalisations are common, especially in unselected populations, but few articles report this and do so poorly. Routine, standardised reporting of ED+H during chemotherapy should be included in RCT reports and evaluated in routine care following adoption of new treatments. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results